Search clinical trials for: Neoadjuvant and adjuvant durvalumab

Total 9383 results

Asan Medical Center

Active, not recruiting

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Korea, Republic of
University Hospital Inselspital, Berne
Celgene

Withdrawn

Durvalumab in DLBCL After Autologous Transplant (IDA-D)

Lymphoma, Large B-Cell, Diffuse
Asan Medical Center

Recruiting

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
University Hospital, Lille
Ministry of Health, France

Recruiting

Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study. (KARCHER-1)

Hepatocellular Carcinoma

France
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

United States, Colombia
Tianjin Medical University Cancer Institute and...

Unknown

Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO

Unresectable Esophageal Cancer

China
The University of Texas Medical Branch, Galveston
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
Elizabeth Dudnik

Recruiting

Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

Patients With Advanced Treatment Naive LCNEC

Israel
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Recruiting

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

Early Small (cT1N0) Triple Negative Breast Cancer

France
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

Canada, Spain, United Kingdom
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC)

India
IRCCS Policlinico S. Matteo

Active, not recruiting

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Lung Cancer | Lung Cancer Stage III

Italy
Mario Negri Institute for Pharmacological Research

Completed

Diadem to Investigate the Activity and Safety of Durvalumab (Diadem)

Pleura Mesothelioma

Italy
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
Sun Yat-sen University

Recruiting

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
MabVax Therapeutics, Inc.

Completed

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

United States
Roswell Park Cancer Institute

Completed

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Hospital Vall d'Hebron

Recruiting

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Unresectable Cholangiocarcinoma

Spain
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

Breast Cancer

United States
Barbara Ann Karmanos Cancer Institute
AstraZeneca

Withdrawn

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Intrahepatic Cholangiocarcinoma Recurrent
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate

Prostate Cancer

United States
Ankara Etlik City Hospital

Completed

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Bladder Cancer | Bladder Cancer Stage I | Bladder Cancer Stage II

Turkey
Vastra Gotaland Region
AstraZeneca

Recruiting

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)

NSCLC, Stage I

Finland, Norway, Sweden
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

Advanced or Metastatic NSCLC

Russian Federation
AstraZeneca

Active, not recruiting

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

Biliary Tract Neoplasms

France, Italy, United States, Thailand, Korea, Republic of, United Kingdom, India, Japan, Poland, Russian Federation, Turkey, China, Taiwan, Hong Kong, Chile, Bulgaria, Argentina
AstraZeneca

Completed

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)

Non-small Cell Lung Cancer

Italy, Poland, France, Spain, United States, Russian Federation
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
MedImmune LLC

Completed

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Solid Tumors

United States, Korea, Republic of, Australia
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Eli Lilly and Company
AstraZeneca

Terminated

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Solid Tumor
Washington University School of Medicine
AstraZeneca

Terminated

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Kidney Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Cancer of the Ovary | Renal Cancer | Colorectal Carcinoma | Ovary Cancer | Cancer of Breast | Gastroesophageal Cancer | Cancer of the Pancreas | Cancer of the Breast | Cancer... and other conditions

United States
Singapore General Hospital
Celgene

Unknown

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

LYMPHOMA

Singapore
AGO Research GmbH

Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

Epithelial Ovarian Cancer

Germany
Arbutus Biopharma Corporation

Recruiting

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Hepatitis B, Chronic

Hong Kong, Spain, Taiwan, Thailand, United Kingdom, Poland, Georgia, Romania
AstraZeneca
Parexel

Recruiting

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO)

Non-Muscle- Invasive Bladder Cancer

United States
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
ETOP IBCSG Partners Foundation
Takeda

Recruiting

Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)

NSCLC, Stage III | ALK-rearrangement

France, Spain, Italy, Poland, United Kingdom
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Spanish Lung Cancer Group

Completed

Durvalumab in HIV-1 Patients With Solid Tumors

Cancer | HIV

Spain
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, France, Germany
AstraZeneca

Completed

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Solid Tumors

United States, France
AstraZeneca

Suspended

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (SOUND)

Lung Cancer

China
AstraZeneca
Parexel; Iqvia Pty Ltd; Medidata Solutions; CISCRP

Active, not recruiting

Durvalumab Long-Term Safety and Efficacy Study (WAVE)

Solid Tumor

Spain, United Kingdom, United States, Canada, Czechia, Poland, Romania, Thailand, Vietnam, Belgium, France, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Malaysia, Taiwan, Australia, Germany, Turkey, Ukraine, Nethe... and more
Se-Hoon Lee
AstraZeneca

Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (SUKSES-N4)

Small Cell Lung Cancer

Korea, Republic of

Search clinical trials for: Neoadjuvant and adjuvant durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations